Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305351 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
A Phase 1 study, sponsored by Kallyope.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT06305351: Completed Phase 1 study, sponsored by Kallyope.
NCT06305351 is a Phase 1 study that has completed, run by Kallyope. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06305351, a Phase 1 study, has completed, sponsored by Kallyope.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)
Interventions
- DRUG K-757 and K-833 QD
- DRUG K-757 and K-833 BID
- DRUG Matching placebo to K-757 and K-833 QD
- DRUG Matching placebo to K-757 and K-833 BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-12-07 |
| Est. Completion | 2024-06-21 |
| Phase | Phase 1 |
What the finished NCT06305351 record still lists
NCT06305351 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 4 interventions - of which K-757 and K-833 QD is the first listed.
NCT06305351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06305351 about?
NCT06305351 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes". This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)
What is the current status of trial NCT06305351?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2023-12-07. Estimated completion is 2024-06-21.
What interventions are being tested in trial NCT06305351?
The interventions under investigation include: K-757 and K-833 QD (DRUG), K-757 and K-833 BID (DRUG), Matching placebo to K-757 and K-833 QD (DRUG), Matching placebo to K-757 and K-833 BID (DRUG).
Who is sponsoring clinical trial NCT06305351?
This trial is sponsored by Kallyope, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06305351's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI